Anti-cancer PEG-enzymes: 30 years old, but still a current approach
- 1 January 2008
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 60 (1) , 69-78
- https://doi.org/10.1016/j.addr.2007.04.018
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Polymer conjugates as anticancer nanomedicinesNature Reviews Cancer, 2006
- PEGylation, successful approach to drug deliveryDrug Discovery Today, 2005
- CT-2103: A Novel Macromolecular Taxane with Potential Advantages Compared with Conventional TaxanesClinical Lung Cancer, 2004
- The enzyme as drug: application of enzymes as pharmaceuticalsCurrent Opinion in Biotechnology, 2003
- Prevention and Treatment of Hyperuricemia in Hematological MalignanciesClinical Lymphoma, 2002
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- Rasburicase: a potent uricolytic agentExpert Opinion on Pharmacotherapy, 2002
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999
- EVIDENCE THAT THE L-ASPARAGINASE OF GUINEA PIG SERUM IS RESPONSIBLE FOR ITS ANTILYMPHOMA EFFECTSThe Journal of Experimental Medicine, 1963
- REGRESSION OF TRANSPLANTED LYMPHOMAS INDUCED IN VIVO BY MEANS OF NORMAL GUINEA PIG SERUMThe Journal of Experimental Medicine, 1953